Overview

Substance Use Disorder (SUD)-Associated Infections' Treatment With Dalbavancin ENabling OUtpatient Transition

Status:
Enrolling by invitation

Trial end date:
2024-04-29

Target enrollment:

Participant gender:

Summary

The Investigators aim to study the outcomes of serious infections due to vancomycin susceptible infections in gram-positive organisms susceptible to vancomycin in people who use drugs (PWUD). The Investigators hypothesize, that a simplified 2-dose dalbavancin regimen, will improve compliance with antimicrobial therapy and that it may facilitate engagement in the treatment of the underlying substance use disorder, and particularly injection drug use - often the true etiology behind these severe infections.

Phase:

Phase 2/Phase 3

Details

Lead Sponsor:

University of Colorado, Denver

Treatments:

Dalbavancin